Display options
Cite
Lin J, Hao C, Gong Y, et al. Effect of Tetramethylpyrazine on Neuroplasticity after Transient Focal Cerebral Ischemia Reperfusion in Rats. Evid Based Complement Alternat Med. 2021;2021:1587241doi: 10.1155/2021/1587241.
Lin, J., Hao, C., Gong, Y., Zhang, Y., Li, Y., Feng, Z., Xu, X., Huang, H., & Liao, W. (2021). Effect of Tetramethylpyrazine on Neuroplasticity after Transient Focal Cerebral Ischemia Reperfusion in Rats. Evidence-based complementary and alternative medicine : eCAM, 20211587241. https://doi.org/10.1155/2021/1587241
Lin, Junbin, et al. "Effect of Tetramethylpyrazine on Neuroplasticity after Transient Focal Cerebral Ischemia Reperfusion in Rats." Evidence-based complementary and alternative medicine : eCAM vol. 2021 (2021): 1587241. doi: https://doi.org/10.1155/2021/1587241
Lin J, Hao C, Gong Y, Zhang Y, Li Y, Feng Z, Xu X, Huang H, Liao W. Effect of Tetramethylpyrazine on Neuroplasticity after Transient Focal Cerebral Ischemia Reperfusion in Rats. Evid Based Complement Alternat Med. 2021 Jan 18;2021:1587241. doi: 10.1155/2021/1587241. eCollection 2021. PMID: 33531914; PMCID: PMC7834793.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2021 Jan 18;2021:1587241. doi: 10.1155/2021/1587241. eCollection 2021.

Effect of Tetramethylpyrazine on Neuroplasticity after Transient Focal Cerebral Ischemia Reperfusion in Rats.

Evidence-based complementary and alternative medicine : eCAM

Junbin Lin, Chizi Hao, Yu Gong, Ying Zhang, Ying Li, Zhihe Feng, Xiangdong Xu, Hailong Huang, Weijing Liao

Affiliations

  1. Department of Neurological Rehabilitation, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan 430071, Hubei, China.

PMID: 33531914 PMCID: PMC7834793 DOI: 10.1155/2021/1587241

Abstract

Tetramethylpyrazine (TMP) has been widely used in ischemic stroke in China. The regulation of neuroplasticity may underlie the recovery of some neurological functions in ischemic stroke. Middle cerebral artery occlusion (MCAO) model was established in this study. Rats were divided into three groups: sham group, model group, and TMP group. The neurological function was evaluated using modified neurological severity score (mNSS). Following the neurological function test, expression of synaptophysin (SYP) and growth-associated protein 43 (GAP-43) were analyzed through immunohistochemistry at 3 d, 7 d, 14 d, and 28 d after MCAO. Finally, the synaptic structural plasticity was investigated using transmission electron microscopy (TEM). The TMP group showed better neurological function comparing to the model group. SYP levels increased gradually in ischemic penumbra (IP) in the model group and could be enhanced by TMP treatment at 7 d, 14 d, and 28 d, whereas GAP-43 levels increased from 3 d to 7 d and thereafter decreased gradually from 14 d to 28 d in the model group, which showed no significant improvement in the TMP group. The results of TEM showed a flatter synaptic interface, a thinner postsynaptic density (PSD), and a wider synaptic cleft in the model group, and the first two alterations could be ameliorated by TMP. Then, a Pearson's correlation test revealed mNSS markedly correlated with SYP and synaptic ultrastructures. Taken together, TMP is capable of promoting functional outcome after ischemic stroke, and the mechanisms may be partially associated with regulation of neuroplasticity.

Copyright © 2021 Junbin Lin et al.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

  1. Brain Circ. 2019 Jan-Mar;5(1):8-11 - PubMed
  2. Neurobiol Learn Mem. 2017 Nov;145:75-83 - PubMed
  3. Neurol Res. 2010 Jun;32(5):547-55 - PubMed
  4. Exp Neurol. 2005 Jun;193(2):291-311 - PubMed
  5. Stem Cells Dev. 2019 Jul 1;28(13):871-881 - PubMed
  6. Brain Res. 2001 Jun 8;903(1-2):94-101 - PubMed
  7. Nat Rev Neurosci. 2009 Dec;10(12):861-72 - PubMed
  8. Neural Regen Res. 2015 Jul;10(7):1076-81 - PubMed
  9. Transl Stroke Res. 2015 Feb;6(1):50-9 - PubMed
  10. J Stroke. 2018 Jan;20(1):57-70 - PubMed
  11. Lancet Neurol. 2019 May;18(5):439-458 - PubMed
  12. Brain Circ. 2018 Jul-Sep;4(3):99-108 - PubMed
  13. Stroke. 1981 Nov-Dec;12(6):723-5 - PubMed
  14. Behav Brain Res. 2019 Apr 1;361:32-38 - PubMed
  15. Neural Plast. 2019 Feb 27;2019:9708905 - PubMed
  16. iScience. 2018 Jun 29;4:190-203 - PubMed
  17. Neuroscientist. 2008 Apr;14(2):139-46 - PubMed
  18. Stroke. 2002 May;33(5):1369-75 - PubMed
  19. Oncol Lett. 2016 Feb;11(2):1167-1172 - PubMed
  20. Neural Regen Res. 2015 May;10(5):832-40 - PubMed
  21. Lab Anim. 2019 Oct;53(5):478-490 - PubMed
  22. Stroke. 2000 Jan;31(1):223-30 - PubMed
  23. J Neurosci Res. 2016 Mar;94(3):253-65 - PubMed
  24. Cold Spring Harb Perspect Biol. 2012 May 01;4(5): - PubMed
  25. Brain Res. 2014 Jan 16;1543:324-33 - PubMed
  26. Eur J Health Econ. 2019 Feb;20(1):107-134 - PubMed
  27. J Pediatr Neurosci. 2017 Jul-Sep;12(3):215-221 - PubMed
  28. Neurosci Lett. 1980 Apr;17(1-2):27-31 - PubMed
  29. Front Cell Neurosci. 2017 Aug 31;11:266 - PubMed
  30. Braz J Med Biol Res. 2017 Apr 03;50(4):e5561 - PubMed
  31. Toxicology. 2018 Dec 1;410:222-230 - PubMed
  32. Exp Neurol. 2019 Mar;313:60-78 - PubMed
  33. NeuroRx. 2005 Jan;2(1):3-14 - PubMed
  34. Circulation. 2020 Mar 3;141(9):e139-e596 - PubMed
  35. Stroke. 1995 Nov;26(11):2135-44 - PubMed
  36. Neuropeptides. 2018 Oct;71:61-69 - PubMed
  37. APMIS Suppl. 1993;40:25-34 - PubMed
  38. Compr Psychiatry. 2019 Oct;94:152122 - PubMed
  39. Cell Mol Neurobiol. 2017 May;37(4):619-633 - PubMed
  40. Exp Neurol. 2014 Feb;252:47-56 - PubMed
  41. Front Psychiatry. 2018 May 29;9:215 - PubMed
  42. Int J Pharm. 2001 Mar 23;216(1-2):61-6 - PubMed
  43. Chin J Integr Med. 2011 Oct;17(10):750-7 - PubMed
  44. J Stroke Cerebrovasc Dis. 2018 Oct;27(10):2829-2839 - PubMed
  45. Brain Res. 2014 Mar 25;1555:78-88 - PubMed
  46. Curr Atheroscler Rep. 2017 Nov 7;19(12):59 - PubMed
  47. Evid Based Complement Alternat Med. 2015;2015:394926 - PubMed
  48. Int J Neuropsychopharmacol. 2015 Jan 24;18(8): - PubMed

Publication Types